Back in 2019, the FDA issued a warning about the use of paclitaxel-coated devices when treating peripheral artery disease. The agency took back that warning in 2023, but it appears to have made a significant impact on patient care. 

Newer balloon-expandable TAVR valves are associated with much better outcomes for patients presenting with both severe AS and severe MS than older models.

Percutaneous treatment was linked to improved survival and fewer adverse events than surgery when patients presented with both symptomatic severe aortic stenosis and complex coronary artery disease. 

Screening TAVR patients for signs of depression prior to treatment could help providers adapt as necessary and deliver better patient care.

High-risk patients are often treated with medical therapy alone instead of revascularization. However, new data make it clear that these patients can live much longer when treated with PCI or CABG.

This was a moment years in the making for interventional cardiology. A total of 164 training programs participated, and 94% of applicants secured a position. 

As more high-risk patients undergo PCI, what is the best antiplatelet strategy following an initial event-free period of DAPT? Does it change after complex PCI? Researchers aimed to answer these questions, and many others, with new findings published in JAMA Cardiology.

Targeting aortic regurgitation with TAVR valves built to treat aortic stenosis may be the only option a cardiologist has—but valves designed specifically to treat AR are linked to much better outcomes, according to a new meta-analysis. Edwards Lifesciences recently acquired the two companies at the center of this study, JenaValve and JC Medical.